← All organizations
Highest phase reached
Phase 4
First clinical trial
Nov 1, 2001First marketed drug
Mar 28, 1967First NDA
Sep 9, 1993Last known activity
May 29, 2026
Timeline
1870s
- Jan 1, 1878
Shionogi— Founded
2000s
- Oct 12, 2007
doripenem— NDA Secondary Org
- Jan 1, 2008
Sciele— Acquired
- Nov 16, 2009
Addrenex Pharmaceuticals— Acquired
2010s
- Jan 1, 2011
Victory Pharma— Acquired
- Mar 10, 2017
Quatrx Pharmaceuticals Co— Acquired
- Mar 23, 2017
naldemedine— NDA Organization
- May 5, 2017
edaravone— Marketing Organization
- Oct 30, 2019
UMN Pharma Inc.— Acquired
2020s
- May 26, 2020
Tetra Discovery Partners— Acquired
- Jun 26, 2023
Qpex Biopharma, Inc.— Acquired
Drugs by trial phase (105 distinct, 170 trials)
Phase 4 (4 own, 2 via acquisition)
Phase 3 (19 own, 4 via acquisition)
Phase 2 (28 own, 5 via acquisition)
Phase 1 (33 own, 9 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Studied for
- Acquired Immunodeficiency Syndrome
- Atrophy
- Attention Deficit Disorder with Hyperactivity
- Back Pain
- Bacterial Infections
- Carcinoma, Non-Small-Cell Lung
- Cerebral Palsy
- Chronic Pain
- Communicable Diseases
- Constipation
- Coronary Artery Disease
- Coronary Disease
- Cough
- Depression
- Depressive Disorder
- Dermatitis
- Dermatitis, Atopic
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Diabetic Neuropathies
- Disease
- Eczema
- Fibromyalgia
- Fibrosis
- Gastrointestinal Diseases
- Gram-Negative Bacterial Infections
- Healthcare-Associated Pneumonia
- Heart Diseases
- HIV Infections
- Hypercholesterolemia
- Hyperkinesis
- Hyperlipidemia, Familial Combined
- Hyperlipidemias
- Hyperlipoproteinemias
- Infections
- Influenza, Human
- Intellectual Disability
- Intestinal Diseases
- Intraabdominal Infections
- Liver Cirrhosis
- Liver Cirrhosis, Biliary
- Liver Diseases
- Low Back Pain
- Lung Neoplasms
- Mesothelioma
- Myocardial Ischemia
- Myofascial Pain Syndromes
- Neoplasms
- Neuralgia
- Obesity
- Osteoarthritis
- Osteoarthritis, Knee
- Paralysis
- Pneumonia
- Pneumonia, Bacterial
- Pneumonia, Ventilator-Associated
- Premature Birth
- Premature Ejaculation
- Purpura, Thrombocytopenic, Idiopathic
- Pyelonephritis
- Respiratory Aspiration
- Rhinitis
- Rhinitis, Allergic
- Rhinitis, Allergic, Seasonal
- Sialorrhea
- Thrombocytopenia
- Tuberculosis
- Urinary Bladder Neoplasms
- Urinary Tract Infections
- Vaginal Diseases
Marketed drugs (13)
Subsidiaries (7 direct, 8 total across the full acquisition tree)
Recent trials (50)
- NCT03780140Study directorN/A—
- NCT03780140Lead sponsorN/A—
- NCT07214571Lead sponsorPhase 2Dec 1, 2025
- NCT07123155Lead sponsorPhase 2Oct 30, 2025
- NCT07217886Lead sponsorPhase 1Oct 16, 2025
- NCT07104162CollaboratorPhase 1Sep 16, 2025
- NCT07018492Lead sponsorPhase 1Aug 30, 2025
- NCT07018492OfficialPhase 1Aug 30, 2025
- NCT07012005Lead sponsorPhase 1Aug 25, 2025
- NCT07083817CollaboratorPhase 1Aug 13, 2025
- NCT07093580Lead sponsorPhase 1Jul 29, 2025
- NCT07011992Lead sponsorPhase 1Jul 18, 2025
- NCT06928051Lead sponsorPhase 2Jun 6, 2025
- NCT07038551CollaboratorPhase 4Jun 6, 2025
- NCT06776432Lead sponsorPhase 2Apr 2, 2025
Details
- Founded
- Osaka, JP Jan 1, 1878
- First NDA
- Sep 9, 1993
- Last known activity
- May 29, 2026
Designations held
- Fast track
- Priority review